In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata

Journal of Medical Microbiology

Volumn 48, Issue 7, 1999, Pages 663-670

  Defontaine, Alain ^a   Bouchara, Jean Philippe ^b   Declerk, Philippe ^b   Planchenault, Claire ^b   Chabasse, Dominique ^b   Hallet, Jean Noel ^a  

^a Laboratoire de Biochimie   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; ISOCONAZOLE; KETOCONAZOLE; MICONAZOLE; MITOCHONDRIAL DNA; POLYENE; PYRROLE DERIVATIVE; TIOCONAZOLE;

ARTICLE; CANDIDA GLABRATA; CLONE; CROSS RESISTANCE; CULTURE MEDIUM; DIFFUSION; DRUG SENSITIVITY; FUNGUS GROWTH; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0032799412     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-48-7-663     Document Type: Article

References (40)

1. Odds FC. Epidemiological shifts in opportunistic and nosocomial Candida infections: mycological aspects. Int J Antimicrob Agents 1996; 6: 141-144.
2. Nguyen MH, Peacock JE, Morris AJ et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-623.
3. Price MF, Larocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994; 38: 1422-1424.
4. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992; 14 Suppl 1: S161-S169.
5. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed guideline M-27P. Villanova, PA, National Committee for Clinical Laboratory Standards. 1992.
6. Sandven P, Bjørneklett A, Maeland A and the Norwegian Yeast Study Group. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. Antimicrob Agents Chemother 1993; 37: 2443-2448.
7. Casals JB. Tablet sensitivity testing of pathogenic fungi. J Clin Pathol 1979; 32: 719-722.
8. Defontaine A, Lecocq FM, Hallet JN. A rapid miniprep method for the preparation of yeast mitochondrial DNA. Nucleic Acids Res 1991; 19; 185.
9. Defontaine A, Coarer M, Bouchara JP. Contribution of various techniques of molecular analysis to strain identification of Candida glabrata. Microb Ecol Health Dis 1996; 9: 27-33.
10. Locker J, Lewin A, Rabinowitz M. The structure and organization of mitochondrial DNA from petite yeast. Plasmid 1979; 2: 155-181.
11. Stevens DA, Stevens JA. Cross-resistance phenotypes of fluconazole-resistant Candida species: results with 655 clinical isolates with different methods. Diagn Microbiol Infect Dis 1996; 26: 145-148.
12. May JL, King A, Warren CA. Fluconazole disc diffusion testing from the routine laboratory. J Antimicrob Chemother 1997; 40: 511-516.
13. Bille J, Glauser MP and the Fluconazole Global Susceptibility Study Group. Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Eur J Clin Microbiol Infect Dis 1997; 16: 924-928.
14. Vanden Bossche H, Marichal P, Odds FC. Molecular mechanisms of drug resistance in fungi. Trends Microbiol 1994; 2: 393-400.
15. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11; 382-402.
16. Sanglard D, Kuchler K, Ischer F, Pagani J-L, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-2386.
17. R gene. Antimicrob Agents Chemother 1995; 39: 422-426.
18. Prasad R, De Wergifosse P, Goffeau A, Balzi E. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet 1995; 27: 320-329.
19. Joseph-Horne T, Hollomon D, Loeffler RST, Kelly SL. Altered P450 activity associated with direct selection for fungal azole resistance. FEBS Lett 1995; 374: 174-178.
20. Bard M, Lees ND, Barbuch RJ, Sanglard D. Characterization of a cytochrome P450 deficient mutant of Candida albicans. Biochem Biophys Res Commun 1987; 147: 794-800.
21. Albertson GD, Niimi M, Cannon RD, Jenkinson HF. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996; 40: 2835-2841.
22. White TC. Increased mRNA levels of ERGI6, CDR, and MDRI correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997; 41: 1482-1487.
23. Hitchcock CA. Resistance of Candida albicans to azole antifungal agents. Biochem Soc Trans 1993; 21: 1039-1047.
24. Hitchcock CA, Pye GW, Troke PF, Johnson EM, Warnock DW. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 1993; 37: 1962-1965.
25. Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995; 39: 1696-1699.
26. Clark FS, Parkinson T, Hitchcock CA, Gow NAR. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species - possible role for drug efflux in drug resistance. Antimicrob Agents Chemother 1996; 40: 419-425.
27. Vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene M-C. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1992; 36: 2602-2610.
28. Marichal P, Vanden Bossche H, Odds FC et al. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1997; 41: 2229-2237.
29. Barry AL, Brown SD. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J Clin Microbiol 1996; 34: 2154-2157.
30. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39: 2520-2522.
31. Colombo AL, Barchiesi F, McGough DA, Rinaldi MG. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 1995; 33: 535-540.
32. Pfaller MA, Barry AL. In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method. Mycopathologia 1995; 130: 3-9.
33. Cormican MG, Hollis RJ, Pfaller MA. DNA macrorestriction profiles and antifungal susceptibility of Candida (Torulopsis) glabrata. Diagn Microbiol Infect Dis 1996; 25: 83-87.
34. Slonimski PP, Perrodin G, Croft JH. Ethidium bromide induced mutation of yeast mitochondria: complete transformation of cells into respiratory deficient non-chromosomal 'petites'. Biochem Biophys Res Commun 1968; 30: 232-239.
35. Wiseman A, King DJ. Microbial oxygenases and their potential application. In: Wiseman A (ed) Topics in enzyme and fermentation biotechnology, vol 6. Chichester, Ellis Horwood. 1982; 151-206.
36. Uno J, Shigematsu ML, Araï T. Primary site of action of ketoconazole on Candida albicans. Antimicrob Agents Chemother 1982; 21: 912-918.
37. Lees ND, Broughton MC, Sanglard D, Bard M. Azole susceptibility and hyphal formation in a cytochrome P-450-deficient mutant of Candida albicans. Antimicrob Agents Chemother 1990; 34: 831-836.
38. Smith KJ, Warnock DW, Kennedy CTC et al. Azole resistance in Candida albicans. J Med Vet Mycol 1986; 24: 133-144.
39. Goodman JL, Winston DL, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
40. Shepp DH, Klosterman A, Siegel MS, Meyers JD. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis 1985; 152: 1257-1263.